There are 2137 resources available
1094P - Demographics, prior therapies and reasons for cemiplimab treatment: Prospective cemiplimAb-rwlc survivorship and epidemiology (C.A.S.E.) study in patients with advanced cutaneous squamous cell carcinoma (CSCC)
Presenter: Guilherme Rabinowits
Session: E-Poster Display
Resources:
Abstract
1095P - Exosomal microRNA in serum is a prognostic factor in cutaneous squamous cell carcinoma
Presenter: jong gwon choi
Session: E-Poster Display
Resources:
Abstract
1096P - Clinicopathologic risk factors for large cell transformation in patients with Sezary syndrome
Presenter: Redina Bardhi
Session: E-Poster Display
Resources:
Abstract
1097P - 4-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma: OpACIN trial
Presenter: Judith Versluis
Session: E-Poster Display
Resources:
Abstract
1098P - Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR: A prospective single arm phase II trial
Presenter: Maartje Rohaan
Session: E-Poster Display
Resources:
Abstract
1100P - Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma
Presenter: John Kirkwood
Session: E-Poster Display
Resources:
Abstract
1101P - Near real-time intraoperative melanoma diagnosis using deep neural networks
Presenter: Ruple Jairath
Session: E-Poster Display
Resources:
Abstract
1102P - Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study
Presenter: Paolo Ascierto
Session: E-Poster Display
Resources:
Abstract
1103P - Long-term survival of real-world advanced melanoma patients treated with targeted therapy
Presenter: Rawa Ismail
Session: E-Poster Display
Resources:
Abstract
1104P - Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO
Presenter: Ralf Gutzmer
Session: E-Poster Display
Resources:
Abstract